Cargando…

Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma

Endometrial carcinoma is the only gynaecologic malignancy with a raising incidence and mortality, posing a major health concern worldwide. The upregulation of programmed death ligand 1 (PD-L1) on tumour cells causes T-cell suppression, which impedes antitumour immunity, promotes immune cell evasion...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chew, Mianxin, Wong, Yin Ping, Karim, Norain, Mustangin, Muaatamarulain, Alfian, Nurwardah, Tan, Geok Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345287/ https://www.ncbi.nlm.nih.gov/pubmed/32545177 http://dx.doi.org/10.3390/diagnostics10060394

Ejemplares similares

Placental Cyclophilin A Expression in Pregnancies Complicated with Hypertension
por: Shaaya, Elia Shazniza, et al.
Publicado: (2022)

SARS-CoV-2 Infection in Pregnancy: Placental Histomorphological Patterns, Disease Severity and Perinatal Outcomes
por: Wong, Yin Ping, et al.
Publicado: (2022)

Prevalence and Histopathological Characteristics of KCNJ5 Mutant Aldosterone-Producing Adenomas in a Multi-Ethnic Malaysian Cohort
por: Mohideen, Syahirah Kaja, et al.
Publicado: (2019)

p40 Immunohistochemistry Is an Excellent Marker in Primary Lung Squamous Cell Carcinoma
por: Affandi, Khairunisa Ahmad, et al.
Publicado: (2018)

Diagnostic Utility of TSSC3 and RB1 Immunohistochemistry in Hydatidiform Mole
por: Chia, Wai Kit, et al.
Publicado: (2023)

A study of HER2 expression in endometrial carcinoma: a single centre experience
por: Hashim, Mariani, et al.
Publicado: (2021)

The Effect of Probiotics (MCP(®) BCMC(®) Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease
por: Mohamad Nor, Mohamad Hizami, et al.
Publicado: (2021)

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
por: Niedźwiedzka-Rystwej, Paulina, et al.
Publicado: (2022)

Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC
por: Ancel, Julien, et al.
Publicado: (2019)

Expression of the Class II and III Beta-Tubulin in Neoplastic and Non-Neoplastic Lymphoid Tissues
por: Yusof, Nor Syahida Binti, et al.
Publicado: (2017)

Loss of CXC-Chemokine Receptor 1 Expression in Chorioamnionitis Is Associated with Adverse Perinatal Outcomes
por: Wong, Yin Ping, et al.
Publicado: (2022)

Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas
por: Rajendran, Madhubala, et al.
Publicado: (2023)

Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection
por: Kwon, Mi Jung, et al.
Publicado: (2017)

Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer
por: Voss, M A, et al.
Publicado: (2011)

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
por: Li, Ying-Fei, et al.
Publicado: (2017)

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
por: Chowdhury, Subrata, et al.
Publicado: (2016)

Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
por: Han, Yeon Bi, et al.
Publicado: (2019)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience
por: Mohd, Rozita, et al.
Publicado: (2021)

Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
por: Gu, Xiaobin, et al.
Publicado: (2016)

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma
por: Lu, Tianzhu, et al.
Publicado: (2020)

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
por: Zhu, Zhenhua, et al.
Publicado: (2017)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group
por: Chang, Hyeyoon, et al.
Publicado: (2016)

Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy
por: Zhang, Fang, et al.
Publicado: (2021)

Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
por: Yun, Sumi, et al.
Publicado: (2019)

Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer
por: Molga-Magusiak, Maria, et al.
Publicado: (2023)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy
por: Jin, Jianjun, et al.
Publicado: (2018)

Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
por: Pirlog, Cristina-Florina, et al.
Publicado: (2022)

The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort
por: Ness, Nora, et al.
Publicado: (2017)

High programmed death-ligand 1 expression is a poor prognostic indicator for esophageal squamous cell carcinoma and is correlated with two-field lymph node metastasis
por: Liang, Mingqiang, et al.
Publicado: (2020)

Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer
por: Lenhard, Miriam, et al.
Publicado: (2013)

Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
por: Yoshida, Kazushige, et al.
Publicado: (2019)

Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
por: Zhong, Jian-Hong, et al.
Publicado: (2016)

High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
por: Guo, Xiaofang, et al.
Publicado: (2018)

Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte‐rich hepatocellular carcinoma
por: Omori, Ginji, et al.
Publicado: (2021)

Prognostic Potential of Alternative Splicing Markers in Endometrial Cancer
por: Wang, Qian, et al.
Publicado: (2019)

Non-Coding RNAs as Prognostic Markers for Endometrial Cancer
por: Piergentili, Roberto, et al.
Publicado: (2021)

GABPA Expression in Endometrial Carcinoma: A Prognostic Marker
por: Ma, Xiaoxue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4s0ghvki86qvsghl5noi0qa8u8